Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?

Anand Anbarasu; Sudha Ramaiah; Paul Livingstone

doi:10.1080/21645515.2020.1773141

Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?

Anand Anbarasu^*, Sudha Ramaiah, Paul Livingstone

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.

Original language	English
Pages (from-to)	2217-2218
Number of pages	2
Journal	Human Vaccines and Immunotherapeutics
Volume	16
Issue number	9
DOIs	https://doi.org/10.1080/21645515.2020.1773141
Publication status	Published - 5 Jun 2020

Keywords

COVID-19
MMR Vaccine
SARS-CoV-2
children
innate immunity
prophylaxis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/21645515.2020.1773141Licence: Free Access/Under Copyright

Cite this

@article{f728a757df0f457c9e1aefa1c33fd905,

title = "Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?",

abstract = "The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.",

keywords = "COVID-19, MMR Vaccine, SARS-CoV-2, children, innate immunity, prophylaxis",

author = "Anand Anbarasu and Sudha Ramaiah and Paul Livingstone",

note = "Publisher Copyright: {\textcopyright} 2020 Taylor & Francis Group, LLC.",

year = "2020",

month = jun,

day = "5",

doi = "10.1080/21645515.2020.1773141",

language = "English",

volume = "16",

pages = "2217--2218",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

number = "9",

}

TY - JOUR

T1 - Vaccine repurposing approach for preventing COVID 19

T2 - can MMR vaccines reduce morbidity and mortality?

AU - Anbarasu, Anand

AU - Ramaiah, Sudha

AU - Livingstone, Paul

PY - 2020/6/5

Y1 - 2020/6/5

N2 - The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.

AB - The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.

KW - COVID-19

KW - MMR Vaccine

KW - SARS-CoV-2

KW - children

KW - innate immunity

KW - prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85086850371&partnerID=8YFLogxK

U2 - 10.1080/21645515.2020.1773141

DO - 10.1080/21645515.2020.1773141

M3 - Article

C2 - 32501133

AN - SCOPUS:85086850371

SN - 2164-5515

VL - 16

SP - 2217

EP - 2218

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 9

ER -

Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this